CiteFacts · FDA Drug Shortages · FDA source
Lorazepam Injection
Status
FDA currently lists this ingredient in shortage.
This is nationwide FDA status, not local pharmacy inventory. CiteFacts does not provide medical, treatment, substitution, or dosing advice.
FDA package and manufacturer records
| Company | Presentation | FDA availability field | FDA update |
|---|---|---|---|
| Amphastar Pharmaceuticals, Inc. | Lorazepam, Injection, 2 mg/1 mL (NDC 76329-8261-1) | Available | 08/18/2026 |
| Fresenius Kabi USA, LLC | Lorazepam, Injection, 2 mg/1 mL (NDC 65219-368-02) | Available | 08/04/2026 |
| Hikma Pharmaceuticals USA, Inc. | Ativan, Injection, 2 mg/1 mL (NDC 0641-6000-10) | Unavailable | 08/13/2026 |
| Hikma Pharmaceuticals USA, Inc. | Ativan, Injection, 2 mg/1 mL (NDC 0641-6001-25) | Limited Availability | 08/13/2026 |
| Hikma Pharmaceuticals USA, Inc. | Ativan, Injection, 4 mg/1 mL (NDC 0641-6002-10) | Unavailable | 08/13/2026 |
| Hikma Pharmaceuticals USA, Inc. | Ativan, Injection, 4 mg/1 mL (NDC 0641-6003-25) | Unavailable | 08/13/2026 |
| Hikma Pharmaceuticals USA, Inc. | Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6044-25) | Limited Availability | 08/13/2026 |
| Hikma Pharmaceuticals USA, Inc. | Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6046-10) | Unavailable | 08/13/2026 |
| Hikma Pharmaceuticals USA, Inc. | Lorazepam, Injection, 4 mg/1 mL (NDC 0641-6045-25) | Unavailable | 08/13/2026 |
| Hikma Pharmaceuticals USA, Inc. | Lorazepam, Injection, 4 mg/1 mL (NDC 0641-6047-10) | Unavailable | 08/13/2026 |
| Hospira, Inc., a Pfizer Company | Lorazepam, Injection, 2 mg/1 mL Syringes (NDC 0409-1985-30) | Limited Availability | 08/07/2026 |
Source facts
Grouped generic ingredient: Lorazepam Injection · 11 package records · Latest FDA row update: 08/18/2026
Therapeutic categories: Neurology
Dosage forms: Injection
Routes: INTRAMUSCULAR, INTRAVENOUS
Open FDA source data · JSON · Markdown
FDA is authoritative. Source retrieved 2026-08-22T15:54:11+00:00. Derived grouping is documented in this record's derivations.